WRAP Retail Offer for up to £1.5 million
Retail offer of up to £1.5 million at 6.0p per share, conditional on shareholder approval.
- WRAP Retail Offer size up to £1.5 million
- Subscription size approximately £7.5 million
- Issue price 6.0 pence per share
- Discount to mid-market close approximately 13.7 per cent
Select text to share a quote on X · sign in to keep highlights & notes in your IMM notes
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce a retail offer via the Winterflood Retail Access Platform ("WRAP") to raise up to £1.5 million (the "WRAP Retail Offer") through the issue of new ordinary shares of 1 penny each in the capital of the Company ("Ordinary Shares"). Under the WRAP Retail Offer 25,000,000 new Ordinary Shares (the "WRAP Retail Offer Shares") will be made available at a price of 6.0 pence per share.
In addition to the WRAP Retail Offer and as announced at 7.00 a.m. on 17 March 2026, the Company is also proposing a subscription of new Ordinary Shares (the "Subscription Shares" and together with the WRAP Retail Offer Shares, the "New Ordinary Shares") to raise approximately £7.5 million (before expenses) at a price of 6.0 pence per Subscription Share (the "Issue Price"). The Issue Price represents a discount of approximately 13.7 per cent. to the mid-market closing price of an Ordinary Share on 16 March 2026 (being the latest practicable date prior to this announcement). The issue price of the WRAP Retail Offer Shares is equal to the Issue Price.
The WRAP Retail Offer and the Subscription are conditional on shareholder approval at a forthcoming general meeting expected to be held on 7 April 2026 and on the New Ordinary Shares being admitted to trading on the London Stock Exchange plc ("Admission"). It is anticipated that Admission will become effective and that dealings in the New Ordinary Shares will commence on AIM, at 8.00 a.m. on 8 April 2026.
WRAP Retail Offer
Therefore, the Company is making the WRAP Retail Offer open to eligible investors in the United Kingdom, being new or existing shareholders of ImmuPharma, following release of this announcement and through certain financial intermediaries.
The Retail Offer is expected to close at 2.00 p.m. on 20 March 2026. Eligible retail investors should note that financial intermediaries may have earlier closing times. The result of the Retail Offer is expected to be announced by the Company on or around 23 March 2026.
There is a minimum subscription of £100 per investor under the Retail Offer. The terms and conditions on which investors subscribe will be provided by the relevant financial intermediaries including relevant commission or fee charges.
| ImmuPharma PLC (www.immupharma.co.uk) Tim McCarthy, Chief Executive Officer Lisa Baderoon, Head of Investor Relations | +44 (0) 207 206 2650 + 44 (0) 7721 413496 |
| SPARK Advisory Partners Limited (NOMAD) Neil Baldwin | +44 (0) 203 368 3550 |
| Stanford Capital Partners (Joint Broker) Patrick Claridge, Bob Pountney | 44 (0) 20 3650 3650 |
| SI Capital (Joint Broker) Nick Emerson | +44 (0) 1483 413500 |
| Winterflood Retail Access Platform Sophia Bechev, Kaitlan Billings | WRAP@winterflood.com +44(0) 20 3100 0214 |
For additional information about ImmuPharma please visit www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.